Stock Events

Stock Events

FibroBiologics 

€3.56
29
-€0.48-11.88% Thursday 07:01

Statistics

Day High
0.178
Day Low
0.178
52W High
1.19
52W Low
0.172
Volume
-
Avg. Volume
-
Mkt Cap
183.18M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

19MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
-0.13
-0.07
-0.02
0.03
Expected EPS
-0.0588653175
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2022
2023
2024
0Revenue
-21.23MNet Income

Analyst Ratings

4.55Average Price Target
The highest estimate is 4.55.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap162.16B
Pfizer is involved in developing therapies for various diseases, including those related to fibrosis, which directly competes with FibroBiologics' focus on fibrotic diseases and regenerative medicine.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences has a strong presence in developing treatments for fibrotic diseases, particularly in liver fibrosis, positioning it as a direct competitor in the fibrosis therapy market.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Vertex Pharmaceuticals focuses on treating cystic fibrosis and other diseases that involve fibrotic processes, making it a key competitor in the fibrosis therapeutic area.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, including treatments for fibrotic diseases, competing in the same biologic space as FibroBiologics.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol-Myers Squibb develops various drugs for fibrotic diseases, including NASH, which overlaps with FibroBiologics' therapeutic areas.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie works on several biologic drugs that target inflammatory and fibrotic diseases, areas that are also key focuses for FibroBiologics.
Novartis
NVS
Mkt Cap304.1B
Novartis offers medications for multiple sclerosis and other chronic diseases involving fibrosis, competing in the same market as FibroBiologics.
AMGEN
AMGN
Mkt Cap236.38B
Amgen produces biologics that treat various fibrotic conditions, directly competing with FibroBiologics in the biotechnology and pharmaceutical sectors.
Merck
MRK
Mkt Cap370.89B
Merck & Co. develops treatments for chronic diseases that can involve fibrotic complications, positioning it as a competitor in the fibrosis treatment market.
Sanofi
SNY
Mkt Cap106.01B
Sanofi focuses on therapies for fibrotic diseases and other chronic conditions, making it a competitor in the same therapeutic areas as FibroBiologics.

About

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Show more...
CEO
ISIN
US31573L1052
WKN
000A3EP67

Listings

F
DE
SG00.F
STU
DE
SG00.STU
MU
DE
SG0.MU
MU
DE
SG00.MU

0 Comments

Share your thoughts

FAQ

What is FibroBiologics stock price today?▼
The current price of SG0.F is €3.56 EUR — it has decreased by -11.88% in the past 24 hours. Watch FibroBiologics stock price performance more closely on the chart.
What is FibroBiologics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange FibroBiologics stocks are traded under the ticker SG0.F.
Is FibroBiologics stock price growing?▼
SG0.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year FibroBiologics has showed a -63.07% decrease.
What is FibroBiologics market cap?▼
Today FibroBiologics has the market capitalization of 183.18M
What is FibroBiologics revenue for the last year?▼
FibroBiologics revenue for the last year amounts to 0 EUR.
What is FibroBiologics net income for the last year?▼
SG0.F net income for the last year is -21.23M EUR.
In which sector is FibroBiologics located?▼
FibroBiologics operates in the Other sector.
When did FibroBiologics complete a stock split?▼
The last stock split for FibroBiologics was on March 30, 2026 with a ratio of 1:20.